"Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Descriptor ID |
D011658
|
| MeSH Number(s) |
C08.381.765
|
| Concept/Terms |
Pulmonary Fibrosis- Pulmonary Fibrosis
- Pulmonary Fibroses
- Fibroses, Pulmonary
- Fibrosis, Pulmonary
Alveolitis, Fibrosing- Alveolitis, Fibrosing
- Alveolitides, Fibrosing
- Fibrosing Alveolitides
- Fibrosing Alveolitis
- Hamman-Rich Syndrome
- Hamman Rich Syndrome
- Syndrome, Hamman-Rich
|
Below are MeSH descriptors whose meaning is more general than "Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Pulmonary Fibrosis".
This graph shows the total number of publications written about "Pulmonary Fibrosis" by people in this website by year, and whether "Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 5 | 0 | 5 |
| 2008 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pulmonary Fibrosis" by people in Profiles.
-
The common ABCA3E292V variant disrupts AT2 cell quality control and increases susceptibility to lung injury and aberrant remodeling. Am J Physiol Lung Cell Mol Physiol. 2021 08 01; 321(2):L291-L307.
-
Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment. BMC Pulm Med. 2016 Jan 12; 16:4.
-
Utility of CT for predicting pulmonary hypertension in patients with parenchymal lung disease: similar results, different conclusion? Chest. 2008 Apr; 133(4):1053-4; author reply 1054.
-
Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. Am J Respir Crit Care Med. 2005 Nov 01; 172(9):1228-9; author reply 1229.
-
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005 Oct 07; 3:61.
-
High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol. 2005 Jul-Aug; 34(4):293-7.
-
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax. 2005 Jul; 60(7):588-94.
-
Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):284-94.
-
Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator. Chest. 2005 Jan; 127(1):275-83.
-
Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol. 2001 Nov; 28(11):2454-9.